Longboard Pharmaceuticals Management
Management criteria checks 3/4
Longboard Pharmaceuticals' CEO is Kevin Lind, appointed in Mar 2020, has a tenure of 4.67 years. total yearly compensation is $2.05M, comprised of 29.7% salary and 70.3% bonuses, including company stock and options. directly owns 0.93% of the company’s shares, worth $21.75M. The average tenure of the management team and the board of directors is 3.8 years and 3.9 years respectively.
Key information
Kevin Lind
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 29.7% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.9% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Oct 15My Strategy For Longboard Pharmaceuticals After Its Big Run
Aug 28We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth
Jul 12
Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely
Mar 16Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?
Oct 03We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate
Dec 25Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth
Sep 10We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely
May 28Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
Feb 11Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation
Oct 27Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business
Jun 12Longboard Pharmaceuticals EPS beats by $0.29
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$76m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$2m | US$610k | -US$54m |
| Sep 30 2023 | n/a | n/a | -US$51m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$572k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$32m |
| Dec 31 2021 | US$875k | US$547k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$29m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$2m | US$332k | -US$14m |
Compensation vs Market: Kevin's total compensation ($USD2.05M) is below average for companies of similar size in the US market ($USD5.50M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
CEO
Kevin Lind (48 yo)
4.7yrs
Tenure
US$2,053,804
Compensation
Mr. Kevin R. Lind serves as President and Chief Executive Officer at Longboard Pharmaceuticals, Inc. since March 2020 and also serves as its director since January 2020. He serves as Director at Ceek Women...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.7yrs | US$2.05m | 0.93% $ 21.8m | |
| Executive VP & CFO | 3.8yrs | US$1.03m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 2.7yrs | US$1.16m | 0.12% $ 2.9m | |
| Executive VP & Head of Operations | no data | no data | no data | |
| Executive VP | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: LBPH's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$2.05m | 0.93% $ 21.8m | |
| Independent Director | 3.9yrs | US$121.80k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$112.80k | 0% $ 0 | |
| Independent Chairman of the Board | 3.9yrs | US$145.81k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$109.34k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$114.81k | 0% $ 0 |
3.9yrs
Average Tenure
57.5yo
Average Age
Experienced Board: LBPH's board of directors are considered experienced (3.9 years average tenure).